Top

Published in:

01-12-2009 | Original Paper

Partner Serostatus and Disclosure Stigma: Implications for Physical and Mental Health Outcomes Among HIV-positive Adults

Authors: Sarit A. Golub, Julia C. Tomassilli, Jeffrey T. Parsons

Published in: AIDS and Behavior | Issue 6/2009

Abstract

This pilot project examined the interaction between partners' serostatus and HIV disclosure-stigma in determining physical and mental health. Participants were 38 sexually active HIV-positive adults. Over 47% of participants reported exclusively seroconcordant partners in the past 30 days. There were no main effects of partner serostatus or disclosure stigma on any of the outcome variables. However, disclosure stigma moderated the relationship between partner serostatus and: number of symptoms reported, pain, physical functioning, quality of life, anxiety, illness intrusiveness, and role-functioning. Future research should explore the implications of partner serostatus for the physical and mental health of HIV-positive individuals.

Berger, B. E., Ferrans, C. E., & Lashley, F. R. (2001). Measuring stigma in people with HIV: Psychometric assessment of the HIV stigma scale. Research in Nursing and Health, 24, 518–529. doi:10.1002/nur.10011.CrossRefPubMed

Butler, D. M., & Smith, D. M. (2007). Serosorting can potentially increase HIV transmissions. AIDS (London, England), 21, 1218–1220. doi:10.1097/QAD.0b013e32814db7bf.

Derlega, J., Winstead, B., Greene, K., Serovich, J., & Elwood, N. (2004). Reasons for HIV disclosure/nondisclosure in close relationships: Testing a model of HIV-disclosure decision making. Journal of Social and Clinical Psychology, 23, 747–767. doi:10.1521/jscp.23.6.747.54804.CrossRef

Derogatis, L. R., & Melisaratos, N. (1983). The brief symptom inventory: An introductory report. Psychological Medicine, 13(3), 595–605.CrossRefPubMed

Devins, G. M., Binik, Y. M., Hutchinson, T. A., Hollomby, D. J., Barré, P. E., & Guttmann, R. D. (1983). The emotional impact of end-stage renal disease: Importance of patients’ perceptions of intrusiveness and control. International Journal of Psychiatry in Medicine, 13(4), 327–343.PubMed

Hazenberg, M. D., Otto, S. A., van Benthem, B. H., Roos, M. T., Coutinho, R. A., Lange, J. M., et al. (2003). Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS (London, England), 17, 1881–1888. doi:10.1097/00002030-200309050-00006.

Heckathorn, D. (2002). Respondent-driven sampling II: Deriving valid population estimates from chain-referral samples of hidden populations. Social Problems, 49, 11–34. doi:10.1525/sp.2002.49.1.11.CrossRef

Helgeson, V. S., Cohen, S., Schulz, R., & Yasko, J. (1999). Education and peer discussion group interventions and adjustment to breast cancer. Archives of General Psychiatry, 56, 340–347. doi:10.1001/archpsyc.56.4.340.CrossRefPubMed

Justice, A. C., Holmes, W., Gifford, A. L., Rabeneck, L., Zackin, R., Sinclair, G., et al. (2001). Development and validation of a self-completed HIV symptom index. Journal of Clinical Epidemiology, 54(12), S77–S90. doi:10.1016/S0895-4356(01)00449-8.CrossRefPubMed

Keegan, A., Lambert, S., & Petrak, J. (2005). Sex and relationships for HIV-positive women since HAART: A qualitative study. AIDS Patient Care and STDs, 19, 645–654. doi:10.1089/apc.2005.19.645.CrossRefPubMed

Lane, J. D., & Wegner, D. M. (1995). The cognitive consequences of secrecy. Journal of Personality and Social Psychology, 69, 237–253. doi:10.1037/0022-3514.69.2.237.CrossRef

Pachankis, J. E. (2007). The psychological implications of concealing a stigma: A cognitive-affective-behavioral model. Psychological Bulletin, 133, 328–345. doi:10.1037/0033-2909.133.2.328.CrossRefPubMed

Parsons, J. T., Scrimshaw, E. W., Wolitski, R. J., Halkitis, P. N., Purcell, D. W., Hoff, C. C., et al. (2005). Sexual harm reduction practices of HIV-Seropositive gay and bisexual men: Serosorting, strategic positioning, and withdrawl before ejaculation. AIDS (London, England), 19(1), S13–S25.

Parsons, T., VanOra, J., Missildine, W., Purcell, W., & Gómez, A. (2004). Positive and negative consequences of HIV disclosure among seropositive injection drug users. AIDS Education and Prevention, 16, 459–475. doi:10.1521/aeap.16.5.459.48741.CrossRefPubMed

Radloff, L. S. (1977). The CES-D scale: A self-report depression scale for research in the general population. Applied Psychological Measurement, 1, 385–401. doi:10.1177/014662167700100306.CrossRef

Southwick, S. M., Vythilingam, M., & Charney, D. S. (2005). The psychobiology of depression and resilience to stress: Implications for prevention and treatment. Annual Review of Clinical Psychology, 1, 255–291. doi:10.1146/annurev.clinpsy.1.102803.143948.CrossRefPubMed

Wu, A. W., Rubin, H. R., Mathews, W. C., Ware, J. E., Brysk, L. T., Hardy, W. D., et al. (1991). A health status questionnaire using 30 items from the medical outcomes study. Medical Care, 29(8), 786–798. doi:10.1097/00005650-199108000-00011.CrossRefPubMed

Title: Partner Serostatus and Disclosure Stigma: Implications for Physical and Mental Health Outcomes Among HIV-positive Adults
Authors: Sarit A. Golub
Julia C. Tomassilli
Jeffrey T. Parsons
Publication date: 01-12-2009
Publisher: Springer US
Published in: AIDS and Behavior / Issue 6/2009
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI: https://doi.org/10.1007/s10461-008-9466-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2009

Changes in Risk Behavior Among HIV-Positive Patients During Their First Year of Antiretroviral Therapy in Cape Town South Africa

AIDS-Related Stigma Among Black and Hispanic Young Adults

Drug Use, High-Risk Sex Behaviors, and Increased Risk for Recent HIV Infection among Men who Have Sex with Men in Chicago and Los Angeles

Psychiatric Context of Acute/Early HIV Infection. The NIMH Multisite Acute HIV Infection Study: IV

From Conceptualizing to Measuring HIV Stigma: A Review of HIV Stigma Mechanism Measures

Psychosocial Characteristics and Sexual Behaviors of People in Care for HIV Infection: An Examination of Men Who Have Sex with Men, Heterosexual Men and Women

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials